These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18090908)

  • 1. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
    Zubor P; Kajo K; Stanclova A; Szunyogh N; Galo S; Dussan CA; Minarik G; Visnovsky J; Danko J
    Eur J Cancer Prev; 2008 Feb; 17(1):33-8. PubMed ID: 18090908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
    Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
    Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
    Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
    Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
    Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
    Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.
    Kamali-Sarvestani E; Talei AR; Merat A
    Cancer Lett; 2004 Nov; 215(1):83-7. PubMed ID: 15374636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
    Naidu R; Yip CH; Taib NA
    Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
    Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
    Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
    Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
    Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
    Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
    Spurdle AB; Hopper JL; Chen X; McCredie MR; Giles GG; Venter DJ; Southey MC; Chenevix-Trench G
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):439-43. PubMed ID: 12010857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite profile in hormonal receptor genes associated with breast cancer.
    Iobagiu C; Lambert C; Normand M; Genin C
    Breast Cancer Res Treat; 2006 Jan; 95(2):153-9. PubMed ID: 16317584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer.
    Tamimi RM; Hankinson SE; Spiegelman D; Colditz GA; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):989-96. PubMed ID: 15184255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
    Hirose K; Matsuo K; Toyama T; Iwata H; Hamajima N; Tajima K
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1407-11. PubMed ID: 15298966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
    Naidu R; Har YC; Taib NA
    J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk.
    González-Zuloeta Ladd AM; Arias Vásquez A; Siemes C; Yazdanpanah M; Coebergh JW; Hofman A; Stricker BH; van Duijn CM
    Breast Cancer Res Treat; 2007 Mar; 101(3):299-304. PubMed ID: 16823505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
    Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
    J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast.
    Schagdarsurengin U; Seidel C; Ulbrich EJ; Kölbl H; Dittmer J; Dammann R
    Int J Oncol; 2005 Jul; 27(1):185-91. PubMed ID: 15942659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.